RESUMO
A selective, rapid, and sensitive liquid chromatography-tandem mass spectrometry(LC-MS/MS) method was developed and validated for the determination of letrozole (LTZ) in human plasma, using anastrozole as internal standard (IS). Sample preparation was performed by one-step protein precipitation with methanol. The analyte and IS were chromatographed on a reversed-phase YMC-ODS-C18 column (2.0 × 100 mm i.d., 3 µm) with a flow rate of 0.3 mL/min. The mobile phase consisted of water containing 0.1% formic acid (v/v) and methanol containing 0.1% formic acid (v/v). The mass spectrometer was operated in selected reaction monitoring mode through electrospray ionization ion mode using the transitions of m/z 286.2 â 217.1 for LTZ and m/z 294.1 â 225.1 for IS, respectively. The method was validated for selectivity, linearity, lower limit of quantitation, precision, accuracy, matrix effects and stability in accordance with the US Food and Drug Administration guidelines. Linear calibration curves were 1.0-60.0 ng/mL. Intra- and inter-batch precision (CV) for LTZ were <9.34%, and the accuracy ranged from 97.43 to 105.17%. This method was successfully used for the analysis of samples from patients treated with LTZ in the dose of 2.5 mg/day. It might be suitable for therapeutic drug monitoring of these patients and contribute to predict the risk of adverse reactions.
Assuntos
Antineoplásicos/sangue , Cromatografia Líquida/métodos , Monitoramento de Medicamentos/métodos , Nitrilas/sangue , Espectrometria de Massas em Tandem/métodos , Triazóis/sangue , Anastrozol , Cromatografia Líquida/economia , Monitoramento de Medicamentos/economia , Humanos , Letrozol , Limite de Detecção , Nitrilas/química , Espectrometria de Massas em Tandem/economia , Triazóis/químicaRESUMO
OBJECTIVE: To compare the pharmacokinetic properties of two newly developed generic ambroxol formulations with a branded innovator product in healthy Chinese male volunteers. METHODS: This was a single-dose, randomized, open-label, three-period crossover study in healthy volunteers aged 18 - 45 years under fasting conditions. Subjects were assigned to receive 1 of 2 test formulations or a reference tablet of ambroxol 30 mg. Each study period was separated by a 1-week washout phase. Blood samples were collected at pre-specified times. A non-compartmental method was employed to determine pharmacokinetic properties (C(max), t(max), AUC(0-tlast), AUC(0-∞)) to test for bioequivalence. The predetermined regulatory range of 90% CI for bioequivalence was 80 - 125%. RESULTS: 24 subjects were enrolled in and completed the study. The geometric mean C(max) values for the test tablet, test capsule, and reference product were 82.73, 85.36, 84.56 ng/mL, and their geometric mean AUC(0-tlast) (AUC(0-∞)) were 660.87 (753.49), 678.98 (756.79), and 639.41 (712.14) ng x h/mL, respectively. For test tablet vs. reference, the 90% CIs of the least squares mean test/reference ratios of C(max), AUC(0-tlast), and AUC(0-∞) were 91.2% to 104.9%, 96.5% to 110.7%, and 98.8% to 113.4%, respectively. For test capsule, the corresponding values were 94.1% to 108.3%, 99.2% to 113.7%, and 99.2% to 113.9%, respectively. No adverse events occurred during the study. CONCLUSIONS: The ambroxol 30 mg tablets and capsules were considered bioequivalent to the reference formulation in accordance with predetermined regulatory criteria.
Assuntos
Ambroxol/farmacocinética , Administração Oral , Adolescente , Adulto , Área Sob a Curva , Química Farmacêutica , Estudos Cross-Over , Voluntários Saudáveis , Humanos , Masculino , Equivalência TerapêuticaRESUMO
OBJECTIVE: To investigate the effects of elesclomol-Cu (ES-Cu) on the proliferation and cuproptosis of human acute myeloid leukemia (AML) cells. METHODS: The effects of ES-Cu on the proliferation of AML cells and the AML cells pre-treated with ammonium tetrathiomolybdate (TTM) were examined by CCK-8 assay. The Calcein/PI kit was used to detected the changes in activity and cytotoxicity of AML cells induced by ES-Cu. Flow cytometry and Cytation3 fully automated cell imaging multifunctional detection system were used to analyze DCFH-DA fluorescence intensity, so as to determine the level of reactive oxygen species (ROS). The GSH and GSSG detection kits were used to measure the intracellular GSH content. Western blot was used to detected the expression of cuproptosis-related proteins ATP7B, FDX1, DLAT and DPYD. RESULTS: ES-Cu inhibited the proliferation of Kasumi-1 and HL-60 cells in a concentration-dependent manner (r Kasumi-1=-0.99ï¼ r HL-60=-0.98). As the concentration of ES-Cu increased, the level of intracellular ROS also increased (P <0.01-0.001). TTM could significantly reverse the inhibitory effect of ES-Cu on cell proliferation and its promoting effect on ROS. With the increase of ES-Cu concentration, the content of GSH was decreased (r =-0.98), and Western blot showed that the protein expressions of ATP7B, FDX1, DLAT and DPYD were significantly reduced (P <0.05). CONCLUSION: ES-Cu can induce cuproptosis in AML cells, which provides a new idea for the treatment of AML.
Assuntos
Proliferação de Células , Hidrazinas , Leucemia Mieloide Aguda , Molibdênio , Espécies Reativas de Oxigênio , Humanos , Proliferação de Células/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo , Células HL-60 , Linhagem Celular Tumoral , Cobre/farmacologiaRESUMO
The aim of present study is to develop a new approach to predicting antioxidative activities of flavonoid extracts from traditional Chinese medicine based on near-infrared spectroscopy (NIR). The 1,1-diphenyl-2-picryl-hydrazyl (DPPH) method was employed to assay the antioxidative activities of twenty-eight extracts. Then, the near infrared diffuse reflectance spectra of those samples were acquired in the range of 4000-10,000 cm(-1). The partial least square (PLS) algorithm was used to generate the calibration model that correlates the spectra and the antioxidative activities of those natural products. The optimal wavenumber ranges and the preprocessing method of original spectrum data were selected during the establishment of calibration model according to the root mean square error of cross-validation (RMSECV). The established model has been successfully applied to predict bioactivities of six samples in the validation set. The value of RMSECV of the proposed model was 9.50% with R2 of 0.9017, and the value of RMSEP was 14.8%. The result indicated that the method can be used for the fast determination of the antioxidative activities of flavonoids as well as other active components of natural products.